LOGO
LOGO

Alpha Teknova Expects 2025 Revenue To Rise By 3% To 11%

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Alpha Teknova Inc. (TKNO), a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, has reported strong financial results for 2024 compared to 2023.

For the fourth quarter ended Dec.31, 2024, the total revenue was $9.3 million, an 18 percent increase from $7.9 million in the same quarter of 2023.

A major chunk of the total revenue comes from its Lab Essentials segment, followed by the Clinical Solutions segment.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.